

The cancer-associated secretory phenotype: a new frontier in targeted therapeutics

Xiaochao Tan,¹ Guan-Yu Xiao,² Priyam Banerjee,³ Shike Wang,⁴ and Jonathan M. Kurie⁴

¹Department of Medicine, Tulane University School of Medicine, New Orleans, Louisiana, USA. ²Department of Toxicology and Cancer Biology, University of Kentucky College of Medicine, Markey Cancer Center, Lexington, Kentucky, USA. ³Bio-Imaging Resource Center, The Rockefeller University, New York, New York, USA. ⁴Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

Following the acquisition of oncogenic mutations, cells undergo senescence and acquire heightened secretory states termed senescence-associated secretory phenotypes (SASPs). Proteins identified in SASPs include a broad range of inflammatory and immune-modulatory cytokines and chemokines, growth factors, and cell surface molecules. In seminal work from the laboratory of Judith Campisi, genotoxic stress was shown to induce senescence partly via SASPs (1). Oncogene expression also induces senescence, and proteins secreted in response to genotoxic stress or oncogenic RAS expression demonstrate a high degree of overlap (1). In work from the laboratory of Dafna Bar-Sagi, mutant RAS activates secretion in established cancer cells that gain tumorigenic activity following ectopic mutant RAS expression (2). Therefore, mutant RAS activates secretion in both senescent and nonsenescent cells. More recently, we identified other oncogenic signals that activate secretory programs in cancer cells, including p53 loss, chromosome 1q and 3q amplicons, and epithelial-mesenchymal transition (3–6). For the purposes of this discussion, oncogene-activated secretory programs in nonsenescent cancer cells will collectively be referred to herein as cancer-associated secretory phenotypes (CASPs).

Distinguishing CASP from SASP

SASPs and CASPs mediate their extracellular actions through partially overlapping sets of secreted effectors (1), but their upstream regulators appear to be distinct. Genotoxic stress activates SASPs through

the transcription factor NF- κ B, which drives the expression of interleukin-6 and -8, indicating that heightened expression of secreted effectors sustains SASPs. Not surprisingly, SASPs are also regulated by classical protein secretory pathway components, including PKD1, ARF1, and PI4KIII β (7). In contrast, somatic mutations activate CASPs by initiating cargo-specific secretory vesicle biogenesis in the Golgi and accelerating anterograde trafficking of secretory vesicles from Golgi to plasma membrane (3, 4, 8). Embedded within the CASP regulatory network are Golgi-resident protein complexes that govern cargo sorting, Golgi membrane bending, and vesicle scission (3, 4, 8, 9). Cargo-sorting proteins recognize and load specific cargos into secretory vesicles (10). In line with these observations, CASPs govern the secretion of specific cargos (3–5).

Secretory blockade as a therapeutic strategy

Based on evidence from preclinical models (11), antibodies and decoy receptors designed to neutralize individual secreted effectors in the extracellular space were tested in patients with cancer (11). These approaches demonstrated limited efficacy (11). While multiple factors could have contributed to these disappointing outcomes, functional redundancy within the cancer secretome may have negated any antitumor activity of the neutralization approaches. Therefore, strategies to block the entire cancer secretome, rather than the actions of single peptides in the extracellular space, warrant consideration. In line with evi-

dence that the cancer secretome contains a broad range of effectors that maintain cancer cell survival and drive immunosuppression and fibrosis in the tumor microenvironment (3, 12), secretory blockade induces apoptosis in tumor cells, restores antitumor immunity, and reverses acquired resistance to immune checkpoint inhibitor therapies in preclinical models (12). Consequently, strategies have been developed based on an understanding of how oncogenic mutations interface with the conventional secretory pathway (Figure 1).

Secretory vesicle biogenesis in the Golgi requires phosphatidylinositol-4-phosphate (PI4P), the Golgi membrane insertion site for Golgi phosphoprotein 3 (GOLPH3), and other proteins that drive vesicle extraction from Golgi membranes (9). Golgi-resident PI4P is generated by two enzymes, PI4KIII β and PI4KII α (13). High levels of these enzymes initiate secretory vesicle biogenesis (3, 5, 14). Selective antagonists of PI4KIII β or PI4KII α induce secretory blockade and tumor regression (3, 5). Sensitivity to these agents is tightly linked to a PI4KIII β -encoding chromosome 1q amplicon and a PI4KII α -upregulating transcriptional program activated by epithelial-mesenchymal transition (Figure 1A) (3, 5).

Golgi-resident scaffolds coordinate client proteins dedicated to a common task (15). The scaffolds Golgi integral membrane protein 4 (GOLIM4) and Golgi reassembly and stacking protein 55 kDa (GRASP55) recruit protein complexes that coordinate cargo loading, Golgi membrane curvature, and vesicle scission to activate CASPs (6, 8). Pharmacologic strategies to degrade GOLIM4 or inhibit GRASP55/client interactions induce secretory blockade and tumor regression (6, 8). Sensitivity to these agents is tightly linked to a GOLIM4-encoding chromosome 3q amplicon (Figure 1B) and a GRASP55-upregulating transcriptional program activated by p53 loss (Figure 1C) (6, 8).

Conflict of interest: JMK is a paid consultant for Terasom Ltd. PB is a paid consultant for ExpertConnect LLC and has spousal income and equity from Eli Lilly and Company. JMK and XT have a pending patent application: "Compositions and methods of treatment for lung cancer" (US 63/483,705).

Copyright: © 2024, Tan et al. This is an open access article published under the terms of the Creative Commons Attribution 4.0 International License.

Reference information: *J Clin Invest.* 2024;134(17):e182652. <https://doi.org/10.1172/JCI182652>.




Figure 1. Blockade of secretory vesicle biogenesis provides a therapeutic strategy for targeting cancer. (A) Phosphatidylinositol-4-phosphate (PI4P) is the Golgi membrane insertion site for Golgi phosphoprotein 3 (GOLPH3), a pivotal regulator of Golgi membrane dynamics and vesicle biogenesis. Golgi PI4P is generated by two Golgi-localized phosphatidylinositol 4-kinases (PI4Ks): PI4KIII β and PI4KII α . PI4K antagonists block PI4P synthesis and impair secretion. (B) Golgi scaffold GOLIM4 recruits effectors of vesicle biogenesis (GOLPH3) and cargo sorting (ATP2C1) to activate secretion. GOLIM4 is degraded by manganese (Mn), resulting in diminished secretion. (C) P53 loss increased the expression levels of the Golgi scaffold GRASP55. GOLGIN45 is a client of GRASP55 and generates a protein complex that promotes vesicle biogenesis. GRASPIN disrupts the interaction between GRASP55 and GOLGIN45. (D) The Golgi scaffold PAQR11 is induced upon the loss of P53. PAQR11 promotes the secretion of PLAU, which functions in an autocrine manner by binding to the PLAUR receptor (PLAUR). Activated PLAUR, in turn, promotes the expression of PAQR11. PLAUR inhibitor (PLAURi) prevents the binding of secreted PLAU to PLAUR, effectively terminating an autocrine signaling pathway that drives secretion.

p53 loss leads to high expression of the Golgi scaffold PAQR11 and enhances the secretion of protease urokinase plasminogen activator (PLAU), which activates autocrine signals that accelerate secretory vesicle biogenesis in the Golgi, completing a prosecretory feed-forward loop in p53-deficient cancer cells (4). Pharmacologic or genetic approaches to interrupt the PLAU-dependent autocrine loop block secretion and inhibit tumor growth and metastasis (4). PLAU secretion and sensitivity to PLAU antagonists are tightly linked to p53 deficiency (Figure 1D) (4).

Candidate secretory antagonists

PI4K antagonists that are under development as antiviral agents inhibit secretion and exert selective antitumor activity against chromosome 1q-amplified malignancies (3). Originally developed as a male contraceptive (16), a small molecule that inhibits GRASP55/client protein interactions inhibits secretion and exerts antitumor activity in p53-deficient tumor models (8). Systemic manganese (Mn) delivery to mice bearing chromosome 3q-amplified malignancies degrades intratumoral GOLIM4, inhibits secretion, and induces tumor regression (6). In a phase I study, intranasal Mn delivery was well tolerated in patients with advanced cancer (17). Given

that chromosome 1q and 3q amplicons are largely mutually exclusive from known actionable oncogenic mutations (3, 6), novel agents are needed for chromosome 1q- and 3q-amplified malignancies. It's important to note that both cancer and healthy cells utilize the same Golgi secretory pathway, suggesting that blocking it could affect noncancerous cells as well. However, cancer cells demonstrate an increased reliance on factors from heightened secretion, driven by the amplification or upregulation of Golgi genes (4–6, 8, 18) or somatic driver mutations (4, 8). This heightened dependency makes cancer cells more sensitive to inhibition of secretion compared with healthy cells, presenting a potential therapeutic window.

Summary

Oncogenic mutations activate secretory programs that drive tumor progression and represent therapeutic targets. The clinical relevance of CASPs is underscored by their prevalence, their linkages to specific genetic and epigenetic contexts, the proven efficacy of secretory blockade in preclinical models, and the availability of assays to identify vulnerable patient populations.

Acknowledgments

This work was supported in part by grants from the NIH (R01CA236781 and R01CA255021-01 to JMK and

5R03CA280382-03 to XT). JMK holds the Gloria Lupton Tension Distinguished Professorship in Lung Cancer.

Address correspondence to: Jonathan M. Kurie, Department of Thoracic/Head and Neck Medical Oncology, Box 432, MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, Texas 77030, USA. Phone: 713.745.1504; Email: jkurie@mdanderson.org. Or to: Xiaochao Tan, Department of Medicine, Section of Hematology and Oncology, Tulane University School of Medicine, New Orleans, Louisiana 70112, USA. Phone: 504.988.1244; Email: xtan4@tulane.edu.

1. Coppe JP, et al. Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. *PLoS Biol.* 2008;6(12):2853–2868.
2. Pylyayeva-Gupta Y, et al. Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia. *Cancer Cell.* 2012;21(6):836–847.
3. Tan X, et al. PI4KIII β is a therapeutic target in chromosome 1q-amplified lung adenocarcinoma. *Sci Transl Med.* 2020;12(527):eaax3772.
4. Tan X, et al. p53 loss activates prometastatic secretory vesicle biogenesis in the Golgi. *Sci Adv.* 2021;7(25):eabf4885.
5. Tan X, et al. EMT-activated secretory and endocytic vesicular trafficking programs underlie a vulnerability to PI4K2A antagonism in lung cancer. *J Clin Invest.* 2023;133(7):e165863.
6. Tan X, et al. Chromosomal 3q amplicon encodes

- essential regulators of secretory vesicles that drive secretory addiction in cancer. *J Clin Invest.* 2024;134(12):e176355.
7. Su Y, et al. The protein kinase D1-mediated classical protein secretory pathway regulates the Ras oncogene-induced senescence response. *J Cell Sci.* 2018;131(6):jcs207217.
8. Tan X, et al. A protumorigenic secretory pathway activated by p53 deficiency in lung adenocarcinoma. *J Clin Invest.* 2021;131(1):e137186.
9. Dippold HC, et al. GOLPH3 bridges phosphatidylinositol-4-phosphate and actomyosin to stretch and shape the Golgi to promote budding. *Cell.* 2009;139(2):337-351.
10. Crevenna AH, et al. Secretory cargo sorting by Ca²⁺-dependent Cab45 oligomerization at the trans-Golgi network. *J Cell Biol.* 2016;213(3):305-314.
11. Coussens LM, et al. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. *Science.* 2002;295(5564):2387-2392.
12. Xiao GY, et al. EMT activates exocytotic Rab5 to coordinate invasion and immunosuppression in lung cancer. *Proc Natl Acad Sci U S A.* 2023;120(28):e2220276120.
13. Graham TR, Burd CG. Coordination of Golgi functions by phosphatidylinositol 4-kinases. *Trends Cell Biol.* 2011;21(2):113-121.
14. Shi L, et al. Addiction to Golgi-resident PI4P synthesis in chromosome 1q21.3-amplified lung adenocarcinoma cells. *Proc Natl Acad Sci U S A.* 2021;118(25):e2023537118.
15. Kulkarni-Gosavi P, et al. Form and function of the Golgi apparatus: scaffolds, cytoskeleton and signalling. *FEBS Lett.* 2019;593(17):2289-2305.
16. Cartier-Michaud A, et al. Genetic, structural, and chemical insights into the dual function of GRASP55 in germ cell Golgi remodeling and JAM-C polarized localization during spermatogenesis. *PLoS Genet.* 2017;13(6):e1006803.
17. Lv M, et al. Manganese is critical for antitumor immune responses via cGAS-STING and improves the efficacy of clinical immunotherapy. *Cell Res.* 2020;30(11):966-979.
18. Tan X, et al. Epithelial-to-mesenchymal transition drives a pro-metastatic Golgi compaction process through scaffolding protein PAQR11. *J Clin Invest.* 2017;127(1):117-131.